BSR_02_0048_A10_S104
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.640
- INTERFERON_GAMMA_RESPONSE+0.560
- MYC_TARGETS_V1+0.530
- E2F_TARGETS+0.510
- MTORC1_SIGNALING+0.490
- ALLOGRAFT_REJECTION+0.470
- INFLAMMATORY_RESPONSE+0.440
- G2M_CHECKPOINT+0.410
- MYC_TARGETS_V2+0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
Top 10 suppressed
- TGF_BETA_SIGNALING-0.350
- WNT_BETA_CATENIN_SIGNALING-0.340
- HEDGEHOG_SIGNALING-0.330
- UV_RESPONSE_DN-0.200
- PROTEIN_SECRETION-0.140
- MYOGENESIS-0.090
- APICAL_SURFACE-0.080
- P53_PATHWAY-0.070
- MITOTIC_SPINDLE-0.060
- HEME_METABOLISM-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_996ZS2A4 | ATRT | — | 0.912 |
| 2 | MDT-AP-0368 | Med | Medulloblastoma | 0.883 |
| 3 | ERR2208906 | — | — | 0.882 |
| 4 | ERR2208905 | — | — | 0.879 |
| 5 | TCGA-A8-A08P-01A-11R-A00Z-07 | — | C | 0.878 |
| 6 | SRR975600 | — | — | 0.874 |
| 7 | f66a9fee-f63a-4398-b242-9c065bbe213d | — | — | 0.871 |
| 8 | TCGA-XF-A9T5-01A-11R-A42T-07 | — | — | 0.870 |
| 9 | SRR1313147 | — | E | 0.866 |
| 10 | TCGA-A2-A0SV-01A-11R-A084-07 | — | C | 0.866 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.640 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.560 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.530 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.490 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.240 | Remibrutinib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| GLYCOLYSIS | 0.230 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |